 SAN RAFAEL, Calif., Aug. 27, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN announced today that the European Commission EC has granted marketing authorization for VOXZOGO vosoritide, a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height. 